[PDF][PDF] Real-world evidence—what is it and what can it tell us

…, MA Robb, J Shuren, R Temple, J Woodcock… - N Engl J Med, 2016 - academia.edu
The term “real-world evidence” is widely used by those who develop medical products or
who study, deliver, or pay for health care, but its specific meaning is elusive. We believe it …

[HTML][HTML] Master protocols to study multiple therapies, multiple diseases, or both

J Woodcock, LM LaVange - New England Journal of Medicine, 2017 - Mass Medical Soc
Master Protocols to Study Multiple Therapies, Multiple Diseases, or Both | NEJM Skip to main
content NEJM Group Follow Us Facebook Twitter Instagram YouTube LinkedIn Prepare to …

Understanding pharmaceutical quality by design

…, MA Khan, SW Hoag, J Polli, GK Raju, J Woodcock - The AAPS journal, 2014 - Springer
This review further clarifies the concept of pharmaceutical quality by design (QbD) and
describes its objectives. QbD elements include the following: (1) a quality target product profile (…

The FDA critical path initiative and its influence on new drug development

J Woodcock, R Woosley - Annu. Rev. Med., 2008 - annualreviews.org
Societal expectations about drug safety and efficacy are rising while productivity in the
pharmaceutical industry is falling. In 2004, the US Food and Drug Administration introduced the …

The prospects for “personalized medicine” in drug development and drug therapy

J Woodcock - Clinical Pharmacology & Therapeutics, 2007 - Wiley Online Library
There has been much recent discussion about the advent of “personalized medicine,” but
controversy exists over its exact definition; how, when, and whether it will be brought about, …

Modernizing pharmaceutical manufacturing: from batch to continuous production

…, CMV Moore, LX Yu, J Woodcock - Journal of …, 2015 - Springer
The Food and Drug Administration (FDA) regulates pharmaceutical drug products to ensure
a continuous supply of high-quality drugs in the USA. Continuous processing has a great …

Biomarkers for Alzheimer's disease: academic, industry and regulatory perspectives

…, WR Sanhai, H Zetterberg, J Woodcock… - Nature reviews Drug …, 2010 - nature.com
Advances in therapeutic strategies for Alzheimer's disease that lead to even small delays in
onset and progression of the condition would significantly reduce the global burden of the …

[HTML][HTML] Contaminated heparin associated with adverse clinical events and activation of the contact system

…, KF Austen, J Woodcock… - … England Journal of …, 2008 - Mass Medical Soc
Background There is an urgent need to determine whether oversulfated chondroitin sulfate (OSCS),
a compound contaminating heparin supplies worldwide, is the cause of the severe …

Oversulfated chondroitin sulfate is a contaminant in heparin associated with adverse clinical events

…, L Robinson, L Buhse, M Nasr, J Woodcock… - Nature …, 2008 - nature.com
Recently, certain lots of heparin have been associated with an acute, rapid onset of serious
side effects indicative of an allergic-type reaction. To identify potential causes for this sudden …

Comparing generic and innovator drugs: a review of 12 years of bioequivalence data from the United States Food and Drug Administration

…, DT Patel, Y Yang, LX Yu, J Woodcock - Annals of …, 2009 - journals.sagepub.com
Background: In the US, manufacturers seeking approval to market a generic drug product must
submit data demonstrating that the generic formulation provides the same rate and extent …